Impact of Pharmacist Managed Pulmonary Arterial Hypertension Program on TYVASO Adherence
Author(s)
Kazumi Patel, MS1, Joaquim Fernandes, MS1, Dingwei Dai, PhD, MD1, Ashley Czonstkowsky, PharmD2, Lucille Accetta, RPh, MPH, MBA2, Jennifer McMahon, PharmD2, Gregg Carmen, RPh2.
1CVS Healthspire, Woonsocket, RI, USA, 2CVS Specialty Pharmacy Therapy Operations, Woonsocket, RI, USA.
1CVS Healthspire, Woonsocket, RI, USA, 2CVS Specialty Pharmacy Therapy Operations, Woonsocket, RI, USA.
Presentation Documents
OBJECTIVES: Pulmonary Arterial Hypertension (PAH) is a chronic condition requiring consistent medication adherence to optimize outcomes. This study aimed to characterize patients enrolled in a CVS Health Pharmacist-Led PAH program for treprostinil (Tyvaso) and evaluate the program’s impact on medication adherence compared to non-participants.
METHODS: This retrospective cohort study included PAH patients filling treprostinil from 1/1/2021 and 3/31/2024. The study group comprised patients enrolled in a CVS pharmacy PAH program, and the control group included non-enrolled patients identified from Aetna claims data during the same period. Characteristics assessed included age, gender, geographic region, rural-urban residency, and Social Vulnerability Index (SVI) quartile. Engagement metrics included duration and completed assessments. Adherence was measured using the proportion of days covered (PDC).
RESULTS: The study group included 2,555 patients and the control group 332 patients. Program engagement was high, with an average of 9 assessments per patient and 46% continuing in the program for over 200 days. Both groups had similar gender distribution (58% female in study vs. 61% in control, p=0.4410) and rural residency (44% in both). Regional distribution differed significantly (p<0.0001), with study group having higher representation from south (36% vs. 31%) and West (20% vs. 7%), while control group had more from Northeast (33% vs. 19%). The study group also had a more vulnerable population, with 15% in the most vulnerable SVI quartile versus 12% in the control group, and a higher average SVI score (0.47 vs. 0.45, p=0.031). The study group was younger (65 vs.71 years average age, p<0.0001). Adherence to treprostinil was significantly higher in the study group with PDC of 0.87 vs 0.78 in control group, p<.0001.
CONCLUSIONS: Enrollment in the PAH program was associated with improved treprostinil adherence. These preliminary results highlight the potential of targeted pharmacy programs to enhance medication adherence and patient outcomes in PAH.
METHODS: This retrospective cohort study included PAH patients filling treprostinil from 1/1/2021 and 3/31/2024. The study group comprised patients enrolled in a CVS pharmacy PAH program, and the control group included non-enrolled patients identified from Aetna claims data during the same period. Characteristics assessed included age, gender, geographic region, rural-urban residency, and Social Vulnerability Index (SVI) quartile. Engagement metrics included duration and completed assessments. Adherence was measured using the proportion of days covered (PDC).
RESULTS: The study group included 2,555 patients and the control group 332 patients. Program engagement was high, with an average of 9 assessments per patient and 46% continuing in the program for over 200 days. Both groups had similar gender distribution (58% female in study vs. 61% in control, p=0.4410) and rural residency (44% in both). Regional distribution differed significantly (p<0.0001), with study group having higher representation from south (36% vs. 31%) and West (20% vs. 7%), while control group had more from Northeast (33% vs. 19%). The study group also had a more vulnerable population, with 15% in the most vulnerable SVI quartile versus 12% in the control group, and a higher average SVI score (0.47 vs. 0.45, p=0.031). The study group was younger (65 vs.71 years average age, p<0.0001). Adherence to treprostinil was significantly higher in the study group with PDC of 0.87 vs 0.78 in control group, p<.0001.
CONCLUSIONS: Enrollment in the PAH program was associated with improved treprostinil adherence. These preliminary results highlight the potential of targeted pharmacy programs to enhance medication adherence and patient outcomes in PAH.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
HSD60
Topic
Health Service Delivery & Process of Care
Disease
SDC: Cardiovascular Disorders (including MI, Stroke, Circulatory), SDC: Rare & Orphan Diseases